HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.

Abstract
L-692,429, a substituted benzolactam, is a novel nonpeptide mimic of the GH secretagogue, GH-releasing peptide-6. The safety and GH secretory activity of L-692,429 (0.001-1.0 mg/kg, i.v.) were investigated in 24 healthy nonobese young (18-26 yr old) male volunteers who demonstrated a GH response of 7 micrograms/L or more after 1 microgram/kg, i.v. GH-releasing hormone [GH-releasing hormone-(1-29)NH2]. L-692,429 was administered as a 15-min iv infusion in an incremental dose, double blind, placebo-controlled, alternating panel fashion to 3 panels of 8 subjects each. Dose-dependent GH secretion was observed with a threshold dose of 0.05 mg/kg (4 of 6 subjects responded with peak GH > 7 micrograms/L), and 0.2 mg/kg produced a response in all 14 subjects tested (mean +/- SE peak GH, 41.0 +/- 6.3 micrograms/L). The maximum dose of 1.0 mg/kg L-692,429 resulted in a pronounced GH response (peak GH, 82.5 +/- 14.9 micrograms/L; n = 8). The GH peak was seen 30-45 min after initiation of the infusion. Small transient increases in cortical and PRL were observed (increases in cortical averaged 182.1 +/- 33.1 nmol/L and peak PRL was 21 +/- 2.6 micrograms/L after 1.0 mg/kg L-692,429, respectively), whereas no significant changes occurred in LH, FSH, TSH, insulin, or glucose concentrations. Plasma pharmacokinetic analysis revealed dose-related increases in plasma concentrations of L-692,429 and a half-life of 3.8 +/- 0.2 (+/- SE) h, a plasma clearance of 214 +/- 67 mL/min, and a steady state volume of distribution of 14.2 +/- 4.8 L. Facial flushing or a warm sensation were reported in 4 subjects, primarily at dose levels of 0.2 mg/kg L-692,429 or more, but no other clinical or laboratory adverse experiences appeared related to drug treatment. L-692,429, synthesized as a specific nonpeptide mimic of GH-releasing peptide-6, is thus a well tolerated, highly effective, and selective GH secretagogue in man.
AuthorsB J Gertz, J S Barrett, R Eisenhandler, D A Krupa, J M Wittreich, J R Seibold, S H Schneider
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 77 Issue 5 Pg. 1393-7 (Nov 1993) ISSN: 0021-972X [Print] United States
PMID8077339 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Benzazepines
  • Hormones
  • Oligopeptides
  • Placebos
  • Tetrazoles
  • L 692429
  • growth hormone releasing hexapeptide
  • Prolactin
  • Growth Hormone
  • Growth Hormone-Releasing Hormone
  • Hydrocortisone
Topics
  • Adolescent
  • Adult
  • Benzazepines (adverse effects, blood, pharmacology)
  • Double-Blind Method
  • Growth Hormone (blood)
  • Growth Hormone-Releasing Hormone (pharmacology)
  • Hormones (blood)
  • Humans
  • Hydrocortisone (blood)
  • Male
  • Oligopeptides (pharmacology)
  • Osmolar Concentration
  • Placebos
  • Prolactin (blood)
  • Tetrazoles (adverse effects, blood, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: